Adcetris(brentuximab vedotin)
Adcetris (brentuximab vedotin) is an antibody drug conjugate pharmaceutical. Brentuximab vedotin was first approved as Adcetris on 2011-08-19. It is used to treat hodgkin disease and large-cell lymphoma immunoblastic in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against tumor necrosis factor receptor superfamily member 8.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Adcetris
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adcetris | Biologic Licensing Application | 2023-06-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hodgkin disease | — | D006689 | C81 |
| large-cell lymphoma immunoblastic | — | D016400 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
brentuximab vedotin, Adcetris, Seagen Inc. | |||
| 2029-11-10 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9042 | Injection, brentuximab vedotin, 1 mg |
Clinical
Clinical Trials
188 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | — | C81 | 30 | 51 | 9 | 1 | 6 | 82 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 13 | 14 | 1 | 1 | 2 | 25 |
| Lymphoma | D008223 | — | C85.9 | 3 | 6 | — | 1 | 2 | 10 |
| T-cell lymphoma | D016399 | — | — | 2 | 4 | 1 | 1 | 1 | 9 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 7 | 12 | 1 | — | 2 | 19 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 6 | 1 | — | — | 9 |
| Mycosis fungoides | D009182 | — | C84.0 | 3 | 4 | 1 | — | — | 8 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 4 | 2 | 1 | — | 2 | 8 |
| Primary cutaneous anaplastic large cell lymphoma | D054446 | — | C86.6 | — | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma peripheral | D016411 | — | — | 5 | 8 | — | — | 2 | 14 |
| Sezary syndrome | D012751 | — | C84.1 | 2 | 2 | — | — | — | 4 |
| B-cell lymphoma | D016393 | — | — | 1 | 4 | — | — | — | 4 |
| Enteropathy-associated t-cell lymphoma | D058527 | — | C86.2 | — | 4 | — | — | — | 4 |
| Adult t-cell leukemia-lymphoma | D015459 | — | C91.5 | 1 | 4 | — | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | — | 4 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | 3 | — | — | — | 3 |
| Lymphomatoid papulosis | D017731 | — | C86.6 | — | 3 | — | — | — | 3 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | 1 | 3 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 3 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell leukemia | D015458 | — | — | 1 | — | — | — | — | 1 |
| Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | — | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Brentuximab vedotin |
| INN | brentuximab vedotin |
| Description | Brentuximab Vedotin (chimeric mab) |
| Classification | Antibody |
| Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1742994 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08870 |
| UNII ID | 7XL5ISS668 (ChemIDplus, GSRS) |
Target
Agency Approved
TNFRSF8
TNFRSF8
Organism
Homo sapiens
Gene name
TNFRSF8
Gene synonyms
CD30, D1S166E
NCBI Gene ID
Protein name
tumor necrosis factor receptor superfamily member 8
Protein synonyms
CD30, CD30L receptor, cytokine receptor CD30, Ki-1 antigen, Lymphocyte activation antigen CD30
Uniprot ID
Mouse ortholog
Tnfrsf8 (21941)
tumor necrosis factor receptor superfamily member 8 (Q60846)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,524 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adcetris
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,574 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use